Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632554 | 0.86 | ALDH1A1 (0.40) | CYP2D6LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL18342994 | 0.83 | ALDH1A1 (0.40) | CYP2D6SMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL5815457 | 0.81 | CHRM2 (0.40) | CYP2D6SLC6A3LMNAMEN1KMT2A | |
| SCHEMBL515918 | 0.80 | SLC6A4 (0.44) | CYP2D6SMN1; SMN2SLC6A3MAPK1 | |
| SCHEMBL28899706 | 0.79 | OPRM1 (0.43) | ALDH1A1 | |
| SCHEMBL516716 | 0.78 | LMNA (0.37) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL516114 | 0.78 | SRC (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL29735511 | 0.78 | GRIN2D (0.48) | CYP2D6CYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17023938 | 0.73 | GABBR2 (0.41) | GABBR2GABBR1TAAR1HTR2ACYP2D6 | |
| SCHEMBL517632 | 0.72 | ALOX5 (0.41) | CYP2D6CYP1A2EPHX1SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| EP-2414323-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | Pierre Fabre Médicament (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
| WO-2010112597-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | GABBR2 545/4885GABBR1 626/4885TAAR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.